1.Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications.
Srushti M TAMBE ; Suraj MALI ; Purnima D AMIN ; Mozaniel OLIVEIRA
Journal of Integrative Medicine 2023;21(3):236-244
Cannabidiol (CBD), a nonpsychotropic phytocannabinoid that was once largely disregarded, is currently the subject of significant medicinal study. CBD is found in Cannabis sativa, and has a myriad of neuropharmacological impacts on the central nervous system, including the capacity to reduce neuroinflammation, protein misfolding and oxidative stress. On the other hand, it is well established that CBD generates its biological effects without exerting a large amount of intrinsic activity upon cannabinoid receptors. Because of this, CBD does not produce undesirable psychotropic effects that are typical of marijuana derivatives. Nonetheless, CBD displays the exceptional potential to become a supplementary medicine in various neurological diseases. Currently, many clinical trials are being conducted to investigate this possibility. This review focuses on the therapeutic effects of CBD in managing neurological disorders like Alzheimer's disease, Parkinson's disease and epilepsy. Overall, this review aims to build a stronger understanding of CBD and provide guidance for future fundamental scientific and clinical investigations, opening a new therapeutic window for neuroprotection. Please cite this article as: Tambe SM, Mali S, Amin PD, Oliveira M. Neuroprotective potential of Cannabidiol: Molecular mechanisms and clinical implications. J Integr Med. 2023; 21(3): 236-244.
Humans
;
Cannabidiol/therapeutic use*
;
Neuroprotection
;
Cannabinoids/therapeutic use*
;
Epilepsy/drug therapy*
;
Cannabis
;
Neuroprotective Agents/therapeutic use*
2.Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation.
Ashraf DUZAN ; Desiree REINKEN ; Timothy L MCGOMERY ; Nicholas M FERENCZ ; Jacob M PLUMMER ; Mufeed M BASTI
Journal of Integrative Medicine 2023;21(2):120-129
Globally, it is evident that glioblastoma multiforme (GBM) is an aggressive malignant cancer with a high mortality rate and no effective treatment options. Glioblastoma is classified as the stage-four progression of a glioma tumor, and its diagnosis results in a shortened life expectancy. Treatment options for GBM include chemotherapy, immunotherapy, surgical intervention, and conventional pharmacotherapy; however, at best, they extend the patient's life by a maximum of 5 years. GBMs are considered incurable due to their high recurrence rate, despite various aggressive therapeutic approaches which can have many serious adverse effects. Ceramides, classified as endocannabinoids, offer a promising novel therapeutic approach for GBM. Endocannabinoids may enhance the apoptosis of GBM cells but have no effect on normal healthy neural cells. Cannabinoids promote atypical protein kinase C, deactivate fatty acid amide hydrolase enzymes, and activate transient receptor potential vanilloid 1 (TRPV1) and TRPV2 to induce pro-apoptotic signaling pathways without increasing endogenous cannabinoids. In previous in vivo studies, endocannabinoids, chemically classified as amide formations of oleic and palmitic acids, have been shown to increase the pro-apoptotic activity of human cancer cells and inhibit cell migration and angiogenesis. This review focuses on the biological synthesis and pharmacology of endogenous cannabinoids for the enhancement of cancer cell apoptosis, which have potential as a novel therapy for GBM. Please cite this article as: Duzan A, Reinken D, McGomery TL, Ferencz N, Plummer JM, Basti MM. Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation. J Integr Med. 2023; 21(2): 120-128.
Humans
;
Glioblastoma/pathology*
;
Endocannabinoids/therapeutic use*
;
Brain Neoplasms/pathology*
;
Cell Proliferation
;
Cell Line, Tumor
;
Cannabinoids/therapeutic use*
3.Pharmacological intervention of conditioned fear and its extinction.
Renzhi HUANG ; Zexuan LI ; Huan CHEN ; Yuesheng HUANG ; Liping DING
Journal of Central South University(Medical Sciences) 2012;37(9):968-972
Conditioned fear and its abnormal extinction are involved in the psychopathology of anxiety disorders, such as posttraumatic stress disorder (PTSD). Cognitive enhancing agents have been demonstrated to alter fear extinction in many animal research literatures. The present review has examined the pharmacological role of gamma-aminobutyric acid (GABA), glutamatergic, cholinergic, adrenergic, dopaminergic, and cannabinoid as well as compounds able to alter the epigenetic and neurotrophic mechanism in fear extinction, highlighting great hope for the future treatment of anxiety disorders with new agents based on the fear extinction.
Animals
;
Anxiety Disorders
;
drug therapy
;
psychology
;
Cannabinoids
;
pharmacology
;
therapeutic use
;
Conditioning, Psychological
;
drug effects
;
Extinction, Psychological
;
drug effects
;
Fear
;
drug effects
;
psychology
;
Humans
;
Nootropic Agents
;
pharmacology
;
Stress Disorders, Post-Traumatic
;
drug therapy
;
psychology
;
gamma-Aminobutyric Acid
;
pharmacology
;
therapeutic use
4.Research progress of role of cannabinoid receptor in fibrosis.
Shanshan LI ; Linlin WANG ; Min LIU ; Yanling GAO ; Zhiling TIAN ; Shukun JIANG ; Miao ZHANG ; Dawei GUAN
Chinese Journal of Pathology 2014;43(2):136-138
Animals
;
Cannabinoid Receptor Antagonists
;
therapeutic use
;
Cannabinoids
;
pharmacology
;
Fibrosis
;
metabolism
;
Humans
;
Liver Cirrhosis
;
etiology
;
metabolism
;
therapy
;
Piperidines
;
therapeutic use
;
Pyrazoles
;
therapeutic use
;
Receptor, Cannabinoid, CB1
;
metabolism
;
Receptor, Cannabinoid, CB2
;
metabolism
;
Receptors, Cannabinoid
;
metabolism
;
Scleroderma, Diffuse
;
metabolism
;
Signal Transduction
;
drug effects
;
Skin
;
metabolism
;
Smad Proteins
;
metabolism
;
Transforming Growth Factor beta1
;
metabolism